SEC 13F Intelligence

Managers / Q3 2020 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$1.1B
Q3 2020
Positions
31
Filings on Record
16
2019–present window
Filed
Nov 12, 2020
original filing

Summary

Frazier Management LLC reported $1.1B in U.S.-listed holdings across 31 positions for Q3 2020.

The portfolio is heavily concentrated: ARQT alone accounts for 27.7% of reported value.

Compared with Q2 2020, the fund opened 5 new positions and exited 0.

Portfolio Metrics

Turnover
+10.3%
vs prior filed quarter
Top-10 Concentration
+85.8%
share of reported value
Largest Position
+27.7%
Arcutis Biotherapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 88.8%Other: 11.2%
  • Common Stock · 88.8% · $989M
  • Other · 11.2% · $125M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
FREELINE THERAPEUTICS HLDGSNEW+550.0K550.0K+$9M$9M
RGNXREGENXBIO INCNEW+174.2K174.2K+$5M$5M
CRDFCARDIFF ONCOLOGY INCNEW+260.0K260.0K+$4M$4M
BLUBELLUS HEALTH INC NEWNEW+1.30M1.30M+$3M$3M
MINERVA NEUROSCIENCES INCNEW+550.0K550.0K+$2M$2M
ENTASIS THERAPEUTICS HLDGS ITRIMMED−150.0K200.0K−$628,000$408,000
TREURTRILLIUM THERAPEUTICS INCHELD+33.4K2.79M+$17M$40M
PASSAGE BIO INCHELD+05.01M−$71M$66M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM27.73%$309M10.54M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM19.18%$214M5.83M
3PCVXVAXCYTE INChistory →COM10.24%$114M2.31M
4MIRMMIRUM PHARMACEUTICALS INChistory →COM6.17%$69M3.57M
5PASSAGE BIO INCCOM5.90%$66M5.01M
6IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM3.88%$43M1.31M
7TREURTRILLIUM THERAPEUTICS INChistory →COM NEW3.55%$40M2.79M
8KRYSKRYSTAL BIOTECH INChistory →COM3.46%$39M895.0K
9ANABANAPTYSBIO INChistory →COM3.07%$34M2.32M
10TRANSLATE BIO INCCOM2.67%$30M2.18M
11ALPINE IMMUNE SCIENCES INCCOM2.03%$23M2.57M
12COLLCOLLEGIUM PHARMACEUTICAL INChistory →COM1.76%$20M943.7K
13SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.75%$19M1.32M
14ADVERUM BIOTECHNOLOGIES INCCOM1.33%$15M1.44M
15IVERIC BIO INCCOM1.20%$13M2.36M
16RCKTROCKET PHARMACEUTICALS INChistory →COM1.08%$12M528.0K
17APTINYX INCCOM0.97%$11M3.19M
18FREELINE THERAPEUTICS HLDGSSPONSORED ADS0.77%$9M550.0K
19GRITSTONE ONCOLOGY INCCOM0.49%$5M2.06M
20ALLENA PHARMACEUTICALS INCCOM0.44%$5M3.33M
21RGNXREGENXBIO INCCOM0.43%$5M174.2K
22CIDARA THERAPEUTICS INCCOM0.34%$4M1.31M
23CRDFCARDIFF ONCOLOGY INCCOM0.33%$4M260.0K
24BLUBELLUS HEALTH INC NEWCOM NEW0.27%$3M1.30M
25NABRIVA THERAPEUTICS PLCSHS0.20%$2M4.26M
26SIERRA ONCOLOGY INCCOM NEW0.19%$2M202.8K
27VTV THERAPEUTICS INCCL A0.17%$2M1.06M
28MINERVA NEUROSCIENCES INCCOM0.16%$2M550.0K
29ITERUM THERAPEUTICS PLCSHS0.14%$2M1.54M
30BELLICUM PHARMACEUTICALS INCCOM NEW0.06%$691,000105.1K
31ENTASIS THERAPEUTICS HLDGS ICOM0.04%$408,000200.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.